Cara Therapeutics Inc

Cara Therapeutics Inc (CARA) Stock Analysis

$15.960

-0.661 (-4.14%)At close

Loading chart…
High
16.560
Open
16.170
VWAP
16.12
Vol
237.14K
Mkt Cap
16.65M
Low
15.844
Amount
3.82M
EV/EBITDA, TTM
-0.46

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).

www.caratherapeutics.com

Analyst Ratings (7)

Buy
6 Buy
1 Hold
0 Sell
Current: 15.96
Low
—
Average
—
High
—

Needham

2024-06-13

Price Target

—

Hold

HC Wainwright & Co.

2024-06-13

Price Target

—

Hold

Canaccord Genuity

2024-06-13

Price Target

$1

Hold

Needham

2024-05-23

Price Target

$5

Strong Buy

HC Wainwright & Co.

2024-05-15

Price Target

$3.6

Strong Buy
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cara Therapeutics Inc (CARA) is -1.25, compared to its 5-year average forward P/E of -4.51.

Forward P/E

Fair
5Y Average P/E
-4.51
Current P/E
-1.25
Overvalued
-0.06
Undervalued
-8.95

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-3.01
Current EV/EBITDA
-0.46
Overvalued
0.60
Undervalued
-6.62

Forward P/S

Fair
5Y Average P/S
7.41
Current P/S
6.51
Overvalued
12.94
Undervalued
1.88

Events Timeline

2025-04-14 (ET)

11:53:10

Cara Therapeutics board approves 1-for-3 reverse stock split

2024-12-27 (ET)

06:01:23

Cara Therapeutics announces effective date of 1-for-12 reverse stock split

2024-12-18 (ET)

06:06:07

Cara Therapeutics, Tvardi Therapeutics enter definitive merger agreement

Show More Events

News

Show More News

CARA FAQ — answered by Alphio AI

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

7 analysts cover CARA: 6 rate it Buy, 1 Hold and 0 Sell.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started